Skip to main content
Premium Trial:

Request an Annual Quote

GeneScan Takes 25.1 Percent Stake in MWG, MWG Sells Convertible Bond for 6.5M Euros

NEW YORK, Jan. 3 (GenomeWeb News) - GeneScan Europe has acquired 25.1 percent of MWG Biotech pursuant to a stock-purchase agreement with two major shareholders announced last month.

 

Specific details of the sale, which included 8,656,500 shares of MWG, were not disclosed.

 

GeneScan also has purchased about €2 million in MWG convertible bonds from the shareholders.

 

MWG Biotech said separately that it has sold convertible bonds totaling €6.5 million. Proceeds of the sale will be used to support MWG's ongoing restructuring, the company noted.

 

In November, the company said it expected to raise €10 million through the sale of its convertible bonds.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.